粪便免疫化学检测在基层医疗中安全优化疑似结直肠癌评估的资源利用:系统综述与Meta分析
结果显示,FIT阈值10 µg Hb/g时敏感性87.2%、特异性84.4%;阈值20 µg Hb/g时每1000例仅比10 µg/g多漏诊不足1例CRC。结论认为FIT是评估基层新发下消化道症状患者的首选检测。
要点
- FIT可作为基层有症状患者疑似CRC的分诊检测,阈值10 µg Hb/g敏感性87.2%。
- 阈值20 µg Hb/g时每1000例仅比10 µg/g多漏诊不足1例CRC(患病率2%)。
- 阈值≥150 µg Hb/g作为rule-in检测敏感性64.1%、特异性95.0%。
核心结论
- FIT是评估基层医疗中新发下消化道症状患者的首选检测。
研究设计与样本
- 纳入在基层医疗因腹部症状就诊的成人患者中报告FIT对CRC诊断性能参数的研究。
- 采用双变量模型合成证据,并用Meta回归分析异质性原因。
关键数值与推荐
- FIT阈值≥150 µg Hb/g粪便:敏感性64.1%(95%CI 57.8%至69.9%),特异性95.0%(95%CI 91.2%至97.2%)。
- FIT阈值10 µg/g粪便:敏感性87.2%(95%CI 81.0%至91.6%),特异性84.4%(95%CI 79.4%至88.3%)。
- FIT阈值20 µg Hb/g粪便:相比10 µg Hb/g阈值,每1000例中额外漏诊CRC不足1例(CRC患病率2%)。
临床怎么用
- 在基层医疗中,对因下消化道症状就诊的患者,可优先使用FIT进行分诊以优化转诊资源。
- 可根据当地资源选择FIT阈值,如10 µg/g或20 µg/g,以平衡敏感性与特异性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Implementation of faecal immunochemical tests (FIT) as a triage test in primary healthcare may improve the efficiency of referrals without missing cases of colorectal cancer (CRC). We aim to summarise the performance characteristics of FITs for CRC in symptomatic patients presenting to primary healthcare. DESIGN: We performed a systematic literature review of Medline and EMBASE databases from May 2018 to November 2020. Previous related systematic searches were also adapted to this aim and completed with reference screening. We identified studies performed on adult patients consulting for abdominal symptoms in primary care which reported data such that the FIT diagnostic performance parameters for CRC could be obtained. Bivariate models were used to synthesise available evidence. Meta-regression analysis was performed to evaluate the causes of heterogeneity. RESULTS: Twenty-three studies (69 536 participants) were included (CRC prevalence 0.3%-6.2%). Six studies (n=34 691) assessed FIT as rule in test (threshold of ≥150 µg Hb/g faeces) showing a sensitivity of 64.1% (95% CI 57.8% to 69.9%) and a specificity of 95.0% (95% CI 91.2% to 97.2%). A threshold of 10 µg/g (15 studies; n=48 872) resulted in a sensitivity of 87.2% (95% CI 81.0% to 91.6%) and a specificity of 84.4% (95% CI 79.4% to 88.3%) for CRC. At a 20 µg Hb/g faeces threshold (five studies; n=24 187) less than one additional CRC would be missed per 1000 patients investigated compared with 10 µg Hb/g faeces threshold (CRC prevalence 2%). CONCLUSION: FIT is the test of choice to evaluate patients with new-onset lower gastrointestinal symptoms in primary healthcare.
引用
- Pin-Vieito N, Tejido-Sandoval C, de Vicente-Bielza N, et al. Faecal immunochemical tests safely enhance rational use of resources during the assessment of suspected symptomatic colorectal cancer in primary care: systematic review and meta-analysis. Gut. 2021. PMID: 34108236. doi:10.1136/gutjnl-2021-324856
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。